Common side effects of Avage include: burning sensation, desquamation, erythema, and xeroderma.  See below for a comprehensive list of adverse effects.
Dermatologic side effects associated with Avage(R) topical cream have included desquamation (40%), erythema (34%), burning sensation (26%), dry skin (16%), skin irritation (10%), pruritus (10%), irritant contact dermatitis (8%), stinging (3%), acne (3%), rash (3%), and cheilitis (1%).  Pruritus, erythema, and burning have been reported (in descending order) with Tazorac(R) topical cream in 10% to 23% of psoriasis patients.  Desquamation, dry skin, erythema, and burning sensation have been reported (in descending order) with Tazorac(R) topical cream in 10% to 30% of acne patients.  Irritation, desquamation, stinging, contact dermatitis, dermatitis, eczema, worsening of psoriasis, skin pain, rash, dry skin, and skin inflammation have been reported (in descending order) with Tazorac(R) topical cream in greater than 1% to less than 10% of psoriasis patients.  Pruritus, irritation, face pain, and stinging have been reported with Tazorac(R) topical cream in 1% to 5% of acne patients.  Dermatitis (less than 1%), impetigo (less than 1%), pruritus (less than 1%), local skin reactions, dryness, erythema, peeling, burning/stinging, and itching have been reported with tazarotene topical (the active ingredient contained in Avage) foam.  Pruritus, burning/stinging, erythema, worsening of psoriasis, irritation, and skin pain have been reported (in descending order) with tazarotene topical gel in 10% to 30% of psoriasis patients.  Desquamation, burning/stinging, dry skin, erythema, and pruritus have been reported (in descending order) with tazarotene topical gel in 10% to 30% of acne patients.  Rash, desquamation, irritant contact dermatitis, skin inflammation, fissuring, bleeding, and dry skin have been reported with tazarotene topical gel in 1% to 10% of psoriasis patients.  Irritation, skin pain, fissuring, and skin discoloration have been reported with tazarotene topical gel in 1% to 10% of acne patients.  Psoriasis worsening and sun-induced erythema have also been reported with tazarotene topical gel in psoriasis patients.  Blister, rash, skin discoloration (including skin hyperpigmentation or skin hypopigmentation), and pain have been reported during postmarketing experience with tazarotene topical gel.
Local side effects associated with tazarotene topical (the active ingredient contained in Avage) foam have included application site irritation (14%), application site dryness (7%), application site erythema (6%), application site exfoliation (6%), application site pain (1%), application site photosensitivity (including sunburn; 1%), application site pruritus (1%), application site dermatitis (1%), and application site reactions (including discoloration, discomfort, edema, rash, and swelling; less than 1%).  Localized edema has been reported with tazarotene topical gel in 1% to 10% of acne patients.
Metabolic side effects associated with Tazorac(R) topical cream have included hypertriglyceridemia (greater than 1% to less than 10%).
Other side effects associated with Tazorac(R) topical cream have included peripheral edema (greater than 1% to less than 10%).
Ocular side effects associated with Avage(R) topical cream have included edema, irritation, and inflammation directly related to the eye or eyelid.
Burning or stinging of the skin (severe)
changes in color of the treated skin
deep grooves or lines in the skin
dryness, itching, peeling, or redness of the skin (severe)
pain or swelling of the treated skin
skin rash (in patients with psoriasis only)
Burning or stinging after application
dryness, itching, peeling, or redness of the skin (mild)